<DOC>
	<DOCNO>NCT01808144</DOCNO>
	<brief_summary>This study ass serum uric acid lower effect safety lesinurad combination febuxostat long-term timeframe .</brief_summary>
	<brief_title>Lesinurad Febuxostat Combination Extension Study Gout</brief_title>
	<detailed_description>This Phase 3 extension study ass long-term efficacy safety lesinurad combination febuxostat subject complete double-blind treatment period Study RDEA594-304 .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject able understand study procedures risk involve willing provide write informed consent first study related activity . Subject complete doubleblind treatment period Study RDEA594304 actively receive tolerate study medication ( lesinurad placebo ) febuxostat 80 mg Month 12 visit . Subject male female ; female subject childbearing potential must agree use effective nonhormonal method birth control study least 14 day last dose study medication . Subject medical psychological condition , opinion Investigator and/or Medical Monitor , might create undue risk subject interfere subject 's ability comply protocol requirement , complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gout</keyword>
</DOC>